Equities

Biomx Inc

Biomx Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.3839
  • Today's Change-0.024 / -5.91%
  • Shares traded149.52k
  • 1 Year change+42.18%
  • Beta1.3646
Data delayed at least 15 minutes, as of May 04 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).

  • Revenue in USD (TTM)0.00
  • Net income in USD-26.17m
  • Incorporated2017
  • Employees58.00
  • Location
    Biomx Inc22 Einstein St., Floor 4NESS-ZIONA 7414003IsraelISR
  • Phone+972 723942377
  • Fax+1 8 002535177
  • Websitehttps://www.biomx.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
PHGE:ASQ since
announced
Transaction
value
Adaptive Phage Therapeutics IncDeal completed06 Mar 202406 Mar 2024Deal completed66.91%2.11m
Data delayed at least 15 minutes, as of May 04 2024.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Inhibitor Therapeutics Inc0.00-3.03m20.30m3.00--3.84-----0.0176-0.01760.000.03070.00----0.00-28.9227.48-30.9132.70------------0.000.00-----125.39------
CERo Therapeutics Holdings Inc0.00-2.54m20.32m8.00---------0.3796-0.37960.00-0.92260.00----0.00-9.96---33.80-----------------------279.82------
MEI Pharma Inc72.65m19.84m20.39m46.001.030.34271.010.28072.982.9810.908.930.6425--25.471,579,304.0017.55-25.3120.31-28.59----27.32-122.05----0.00--19.9597.5641.53------
Evaxion Biotech A/S - ADR73.00k-22.13m20.60m49.00------282.18-81.29-81.290.2665-1.250.0042--0.0911,489.80-126.74-100.11-183.85-131.65-----30,308.22-131,560.30---30.921.77------4.51--65.53--
AIM ImmunoTech Inc202.00k-28.96m20.60m26.00--2.08--101.98-0.595-0.5950.00420.20840.0068--0.14137,769.23-96.75-45.64-116.18-48.3579.21-231.75-14,337.62-11,695.01----0.00--43.26-11.26-48.94--35.73--
Serina Therapeutics Inc142.00k-14.80m20.76m4.00--1.64--146.17-13.72-13.720.13165.070.0187--4.6635,500.00-194.80-194.46----71.8385.80-10,430.28-2,347.36---2.030.4489--317.65-36.69-41.49------
Alaunos Therapeutics Inc5.00k-35.14m20.82m1.00--3.30--4,163.25-2.20-2.200.00030.39390.0001--2.005,000.00-96.01-74.83-149.28-89.57-----702,800.00-10,508.06---14.830.00---99.83-49.086.86---15.56--
Eom Pharmaceutical Holdings Inc0.00-4.93m20.84m3.00---------0.0435-0.04350.00-0.0212------0.00---126.34---171.37------------7.41-------254.37------
Biomx Inc0.00-26.17m21.20m58.00--5.73-----0.5433-0.54330.000.0670.00----0.00-74.18---101.74-------------21.950.7841------7.59------
Synlogic Inc3.37m-57.28m21.43m6.00--0.3963--6.36-11.41-11.410.65814.640.0362----561,833.30-61.46-40.57-74.45-43.82-----1,699.26-3,245.93----0.00009--185.685.9913.40---48.05--
Flora Growth Corp76.07m-47.36m21.67m97.00--2.36--0.2848-6.62-7.9710.040.71671.456.7631.13784,237.10-89.22---130.91--23.32---61.35--0.7897--0.2317--127.75---1.87------
TherapeuticsMD Inc1.30m-7.70m21.68m1.00--0.7403--16.65-0.7466-1.000.12492.540.0195----1,302,000.00-11.51-53.35-19.23-111.61100.0086.67-591.32-236.57----0.00---98.14-39.53-816.85------
OncoCyte Corp1.50m-25.80m22.01m43.00--1.07--14.64-3.08-3.470.18693.100.0172--1.2034,953.49-28.41-35.11-31.93-39.7127.48---1,653.69-2,373.36---146.070.00--56.89---34.84--55.41--
NRX Pharmaceuticals Inc0.00-30.16m22.02m2.00---------2.95-2.950.00-0.13980.00-------182.00-120.57---168.40--------------------24.14------
Zivo Bioscience Inc27.65k-7.78m22.14m8.00------800.85-4.62-4.620.0163-0.92590.0206----3,456.25-580.66-376.60----41.99---28,127.23-96,315.32---97.39--------11.07------
Cumberland Pharmaceuticals, Inc.39.55m-6.28m22.40m91.00--0.7537--0.5663-0.4448-0.44482.752.100.45280.83833.45434,643.10-7.25-7.03-10.66-9.5284.6679.95-16.01-17.641.11-25.080.3041---5.856.15-12.73---36.17--
Data as of May 04 2024. Currency figures normalised to Biomx Inc's reporting currency: US Dollar USD

Institutional shareholders

0.77%Per cent of shares held by top holders
HolderShares% Held
Renaissance Technologies LLCas of 31 Dec 2023110.29k0.24%
MM Asset Management, Inc.as of 31 Dec 202396.81k0.21%
Bridgeway Capital Management LLCas of 31 Dec 202349.50k0.11%
Citadel Securities LLCas of 31 Dec 202333.58k0.07%
Walleye Capital LLCas of 31 Dec 202331.48k0.07%
XTX Markets LLCas of 31 Dec 202314.53k0.03%
G1 Execution Services LLCas of 31 Dec 202310.91k0.02%
PNC Bank, NA (Investment Management)as of 31 Dec 20234.00k0.01%
UBS Securities LLCas of 31 Dec 20232.00k0.00%
Bank of America, NA (Private Banking)as of 31 Dec 20231.000.00%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.